1. Meaning and introduction

Creative-Genomics Intellectual Property Governance refers to the legal, ethical, regulatory and institutional framework governing the ownership, protection, commercialisation and use of intellectual property generated through creative applications of genomics.

It concerns the relationship between genomic science and intellectual property (IP), particularly when genetic information, biological materials, artificial intelligence, computational biology and creative technologies are used to develop new inventions, artistic works, diagnostic methods, synthetic organisms, genomic databases and biotechnology products.

The subject raises an important legal question:

Who owns the intellectual property when a human genome, biological sample, computational algorithm or AI system contributes to the creation of a new scientific or commercial product?

For example:

A researcher develops a new therapeutic invention using human genomic data.

A biotechnology company creates a synthetic genetic sequence using computational design.

An AI system generates a new DNA sequence based on existing genomic databases.

An artist transforms genomic information into digital artwork.

A university commercialises inventions developed using donated biological samples.

A pharmaceutical company patents a genetically engineered biological product.

These activities create overlapping legal claims involving inventorship, authorship, consent, privacy, commercial ownership, patentability, copyright and benefit-sharing.

In India, the subject must principally be examined through the Patents Act, 1970, Copyright Act, 1957, Designs Act, 2000, Biological Diversity Act, 2002 (as amended), Digital Personal Data Protection Act, 2023, and constitutional protections under Articles 14, 19 and 21.

Comparative developments in the United States, United Kingdom and European Union are also important.

2. Objectives of intellectual property governance

The principal objectives are:

Protection of innovation: Protect genuine scientific inventions arising from genomic research.

Recognition of creators: Identify legitimate inventors and authors.

Prevention of biological monopolies: Prevent unjustified private ownership over naturally occurring genetic information.

Protection of human dignity: Prevent exploitation of individuals whose biological materials contribute to commercial discoveries.

Research accessibility: Maintain appropriate access to genomic information for scientific and medical research.

Fair commercialisation: Ensure equitable distribution of benefits from genetic resources.

AI accountability: Determine responsibility for AI-assisted genomic inventions.

Protection against misappropriation: Prevent unauthorised commercial exploitation of biological materials and research databases.

3. Major legal dimensions

A. Patent protection of genomic inventions

Patent law is central to creative-genomics governance because genomic research may produce new diagnostic technologies, genetic engineering techniques, synthetic biological constructs, therapeutic applications and industrial biotechnology products.

Under the Indian Patents Act, 1970, an invention must satisfy the requirements of:

Novelty.

Inventive step.

Industrial applicability.

Patentable subject matter.

Compliance with statutory exclusions.

Section 3(c) excludes the discovery of a living thing or non-living substance occurring in nature. Section 3(j) excludes plants and animals, in whole or any part thereof, other than microorganisms, but includes exclusions concerning essentially biological processes for production or propagation.

Section 3(i) also excludes specified methods of medical treatment.

Therefore, discovering a naturally occurring gene or DNA sequence does not automatically create a patentable invention. A genuinely technical invention involving genetic material may require separate examination.

B. Copyright protection of genomic creativity

Copyright may protect original creative expression associated with genomic research, including:

Original scientific illustrations.

Genomic visualisations.

Original software used in genome analysis.

Original research publications.

Digital representations and creative genomic artwork.

Original databases to the extent they satisfy applicable copyright requirements.

However, copyright does not ordinarily protect scientific facts, natural genetic sequences, biological phenomena or abstract ideas themselves.

Under Section 13 of the Copyright Act, 1957, copyright subsists in original literary, dramatic, musical and artistic works, cinematograph films and sound recordings.

Section 2(d) addresses authorship, including computer-generated works. Section 17 establishes the general framework for first ownership, subject to statutory exceptions and agreements.

An important distinction must therefore be maintained between ownership of genomic information and copyright in an original creative representation of that information.

C. Trade secrets and confidential genomic research

Genomic research may involve confidential information such as:

Unpublished genetic discoveries.

Proprietary sequencing methods.

Drug-development algorithms.

Research protocols.

Industrial biotechnology processes.

Confidential genomic datasets.

Indian law does not have a single comprehensive trade secrets statute. Protection is principally developed through contractual obligations, equitable principles and breach-of-confidence jurisprudence.

A company cannot necessarily claim unrestricted ownership of an individual's genetic information merely because the information was collected during a confidential research relationship.

D. Ownership of biological materials and commercial inventions

One of the most difficult questions is whether a person who provides biological material automatically acquires ownership of every invention developed from it.

The law must distinguish between:

Ownership or control of the original biological sample.

Rights concerning personal genetic information.

Patent ownership of a subsequently developed invention.

Copyright in research publications or creative representations.

Contractual rights arising from research participation.

Rights to compensation or benefit-sharing.

Important case: Moore v. Regents of the University of California, 51 Cal.3d 120 (1990).

Facts:

John Moore provided biological samples during medical treatment.

His physician used his cells for research and developed a commercially valuable cell line.

The patient alleged that his cells had been used without adequate disclosure of the research and commercial interests.

Judgment:

The Supreme Court of California rejected the conversion claim based on ownership of the excised cells but recognised that the allegations could support claims concerning breach of fiduciary duty and lack of informed consent.

Legal significance:

The decision illustrates that ownership of a commercially developed invention and a patient's rights concerning the collection and use of biological material are separate legal questions.

It is particularly relevant to genomic research involving commercial exploitation of donated biological materials.

E. Intellectual property and genetic databases

Genomic databases are valuable because they contain extensive biological and genetic information used for:

Disease research.

Drug discovery.

Personalised medicine.

Genetic testing.

Population genomics.

AI-assisted diagnosis.

Biotechnology development.

However, the ownership of a genomic database does not necessarily confer unrestricted ownership of the genetic information of the individuals represented in it.

The legal framework must distinguish between:

Database structure: Original selection, arrangement or organisation may receive copyright protection.

Database contents: Genetic facts are not automatically protected by copyright.

Confidential information: Access may be governed by contractual and confidentiality obligations.

Personal information: Processing must comply with applicable privacy and data-protection legislation.

In India, Article 21 of the Constitution, as interpreted in Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), provides the constitutional foundation for informational privacy and personal autonomy.

Consequently, commercial ownership of a genomic platform should not be treated as an unlimited entitlement to exploit the personal genetic information stored on it.

F. AI-generated genomic inventions

Artificial intelligence has become increasingly important in creative genomics.

AI systems can assist in:

Designing synthetic DNA sequences.

Predicting protein structures.

Developing genetic therapies.

Identifying genetic mutations.

Creating synthetic biological systems.

Producing genomic artwork.

Discovering potential drug targets.

This creates a fundamental question: Can an AI system itself be recognised as an inventor or author?

Under Indian patent law, the inventor and the person entitled to apply for a patent must satisfy the statutory requirements. AI may assist the inventive process, but the legal entitlement cannot simply be transferred to an AI system.

Important comparative case: Thaler v. Vidal, 43 F.4th 1207 (Fed. Cir. 2022).

Facts:
Dr Stephen Thaler sought patent protection for inventions allegedly generated by an artificial intelligence system called DABUS.

Judgment:

The United States Court of Appeals for the Federal Circuit held that an inventor under the US Patent Act must be a natural person.

Legal significance:

The decision demonstrates the difficulty of recognising AI as an independent inventor.

For creative genomics, this principle raises questions about:

Human contribution to AI-assisted DNA design.

Identification of the actual inventor.

Ownership of AI-generated genetic innovations.

Patent entitlement where several researchers and AI systems contribute.

Responsibility for inaccurate or harmful genomic inventions.

AI-assisted invention should therefore be distinguished from genuinely autonomous machine-generated invention.

G. Copyright and creative genomic artwork

Creative genomics can also produce artistic works based on genetic information.

Examples include:

DNA-based digital artwork.

Genetic-pattern visualisations.

Artistic representations of chromosomes.

Computationally generated biological designs.

Interactive genomic installations.

Multimedia works incorporating scientific datasets.

The central copyright question is whether the creative contribution involves original expression rather than merely reproducing scientific facts.

Important case: R.G. Anand v. Delux Films, (1978) 4 SCC 118.

The Supreme Court of India held that copyright does not protect ideas, themes or subject matter as such. Protection applies to the particular form and manner of expression.

Application:

A scientist or artist cannot claim exclusive copyright over a naturally occurring genetic sequence merely by presenting it artistically.

However, an original artistic representation of that sequence may qualify for copyright protection.

Important case: Eastern Book Company v. D.B. Modak, (2008) 1 SCC 1.

The Supreme Court adopted a standard of originality requiring a meaningful degree of skill and judgment rather than merely mechanical labour.

Application:

An original genomic visualisation may qualify for copyright if its selection, arrangement and expression demonstrate sufficient originality.

The mere automatic conversion of genetic data into a standard visual format does not necessarily establish copyright in the resulting work.

H. Genetic resources and benefit-sharing

Creative genomics may involve biological resources obtained from plants, animals and microorganisms.

Commercial inventions derived from these resources can raise questions concerning:

Access permissions.

Research authorisation.

Traditional knowledge.

Community interests.

Intellectual property applications.

Commercialisation.

Benefit-sharing.

India regulates these issues through the Biological Diversity Act, 2002, as amended by the Biological Diversity (Amendment) Act, 2023.

Important provisions include:

The amended Section 6 distinguishes between specified foreign-controlled applicants, who require prior approval, and persons covered by Section 7, who are subject to registration before grant and approval at commercialisation.

The 2023 amendments also expressly exclude human genetic material from the statutory definition of biological resources. Thus, the Act's biological-resource access and benefit-sharing framework should not automatically be applied to human genomic material.

Indian Kanoon+2

Legal significance: Genomic commercialisation must be examined not merely through patent ownership but also through the legal source of biological resources and the applicable benefit-sharing obligations.

4. Important judicial precedents

The following decisions provide the principal comparative jurisprudential foundation for creative-genomics intellectual property governance.

1. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

Highly relevant

Facts:

Myriad Genetics identified the BRCA1 and BRCA2 genes associated with increased breast and ovarian cancer risks and obtained patents relating to them.

Judgment:

The US Supreme Court held that naturally occurring DNA segments are not patentable merely because they have been isolated from the human genome. However, synthetically created complementary DNA (cDNA) may be patent eligible because it is not naturally occurring, subject to the Court's qualifications concerning sequences without introns.

Legal principles:

Natural genetic information cannot be monopolised merely through discovery.

Human ingenuity must produce something distinguishable from a natural phenomenon.

Synthetic biological inventions require separate patentability analysis.

Patent law must balance scientific innovation and public access.

Application in India:

The reasoning is relevant when interpreting Sections 3(c) and 3(j) of the Indian Patents Act, although the US judgment is not binding on Indian courts.

LII / Legal Information Institute+1

2. Diamond v. Chakrabarty, 447 U.S. 303 (1980)

Facts:

An inventor developed a genetically modified bacterium capable of breaking down multiple components of crude oil.

Judgment:

The US Supreme Court held that the genetically engineered microorganism was patentable subject matter because it was a product of human ingenuity with characteristics significantly different from those found in nature.

Legal principles:

Engineered microorganisms may qualify for patent protection.

Human intervention can distinguish an invention from a natural discovery.

Biotechnology innovation may be protected where statutory requirements are satisfied.

Application:

The decision is important for synthetic biology, engineered genomic systems and genetically modified microorganisms.

3. Moore v. Regents of the University of California (1990)

The decision distinguishes a patient's interests in biological materials and informed consent from proprietary rights in a subsequently developed cell line.

Legal significance:

A biotechnology company cannot assume that a patent automatically resolves all questions relating to the original collection and use of human biological materials.

Justia Law+1

4. Greenberg v. Miami Children's Hospital Research Institute, 264 F. Supp. 2d 1064 (S.D. Fla. 2003)

Facts:

Families and researchers contributed resources and information to research concerning Canavan disease. The research eventually produced commercially valuable genetic testing technology.

Judgment:

The US District Court rejected the plaintiffs' conversion and unjust-enrichment claims on the facts, while addressing the significance of informed consent and the research relationship.

Legal significance:

The case demonstrates the tension between:

Collaborative genetic research.

Commercial patent rights.

Donor expectations.

Disclosure of research objectives.

Equitable distribution of research benefits.

5. Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2019) 3 SCC 381

Important Indian precedent

Facts:

The dispute concerned Monsanto's Bt cotton technology and patent rights involving genetically modified plant material.

Judgment:

The Supreme Court set aside the Delhi High Court's decision that had effectively determined patent validity at the interim stage and remanded the matter for proper consideration.

Legal significance:

Biotechnology patent disputes require careful scientific and statutory examination.

Patent rights must be considered alongside plant-variety protection.

Technical complexity should not be resolved through inappropriate summary adjudication.

The relationship between genetic technology and agricultural regulation is legally significant.

The judgment is particularly important for Indian biotechnology patent governance.

Sci API+1

6. Dimminaco AG v. Controller of Patents and Designs, AIR 2002 Cal 55

Facts:

The applicant sought a patent concerning a process for preparing a vaccine containing a live virus.

Judgment:

The Calcutta High Court rejected the proposition that a process could not qualify as an invention merely because the resulting product contained a living organism.

Legal significance:

The decision is important for biological manufacturing and biotechnology inventions.

It demonstrates that the presence of a living organism does not automatically exclude a manufacturing process from patent protection.

Ali on Patents

7. R.G. Anand v. Delux Films, (1978) 4 SCC 118

The Supreme Court distinguished unprotected ideas from protectable original expression.

Application:

A genetic pattern or scientific fact cannot be monopolised through copyright merely because someone first discovered or described it. Original artistic and literary representations may nevertheless be protected.

Indian Kanoon+1

8. Eastern Book Company v. D.B. Modak, (2008) 1 SCC 1

The Supreme Court clarified the originality standard for copyright protection.

Application:

Original genomic databases, software outputs, illustrations and scientific arrangements must demonstrate sufficient original intellectual contribution.

Indian Kanoon

5. Indian constitutional framework

Creative-genomics intellectual property governance is not exclusively an intellectual property issue. It also involves constitutional rights, particularly when genetic information is obtained from human beings or used for commercial purposes.

A. Article 14 – Equality and non-arbitrariness

Article 14 protects equality before the law and equal protection of laws.

Its application includes:

Preventing discriminatory access to genomic technologies.

Ensuring fair allocation of publicly funded genetic research.

Preventing arbitrary exclusion of certain communities from biotechnology benefits.

Ensuring that intellectual property regulations operate consistently.

Preventing unjustified monopolisation of important healthcare technologies.

For example, if a patented genomic diagnostic technology is available only to economically privileged groups, questions of healthcare equality and public-interest regulation may arise.

B. Article 19(1)(g) – Freedom of scientific and commercial activity

Article 19(1)(g) protects the freedom to practise a profession and carry on an occupation, trade or business, subject to reasonable restrictions under Article 19(6).

Its relevance includes:

Biotechnology entrepreneurship.

Scientific research.

Commercial genomic innovation.

Licensing of genetic technologies.

Development of genomic software.

Commercialisation of synthetic biological products.

However, intellectual property rights are statutory rights and must operate within constitutional and public-interest limitations.

C. Article 21 – Privacy, autonomy and dignity

Article 21 is particularly significant where genomic inventions involve human genetic material.

The constitutional framework protects:

Personal autonomy.

Informational privacy.

Bodily integrity.

Human dignity.

Protection against unauthorised exploitation of personal information.

Case: Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1.

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms.

Application to creative genomics:

Individuals should receive meaningful information about genomic data collection.

Research consent should address relevant commercial uses.

Genetic information should receive appropriate security safeguards.

Secondary use should be governed by applicable consent and legal requirements.

Commercialisation should not extinguish the individual's privacy rights.

Case: Selvi v. State of Karnataka, (2010) 7 SCC 263.

The Supreme Court addressed involuntary narco-analysis, polygraph examinations and brain electrical activation profiling.

The judgment is relevant to the constitutional protection against involuntary extraction of personal information and bodily autonomy.

Its principles provide an important foundation for evaluating coercive genomic collection and related investigative practices.

D. Articles 32 and 226 – Constitutional remedies

These provisions provide constitutional remedies where genomic technologies or regulatory authorities violate fundamental rights.

Potential situations include:

Unlawful governmental collection of genomic information.

Arbitrary restrictions on legitimate research.

Violations of informational privacy.

Discriminatory biotechnology regulation.

Failure to provide legally required procedural safeguards.

6. Important statutory framework in India

A. Patents Act, 1970

The following provisions are particularly important:

Section 2(1)(j): Definition of invention.

Section 2(1)(ja): Inventive step.

Section 3(c): Exclusion concerning discoveries of naturally occurring substances and living things.

Section 3(d): Restrictions concerning certain new forms and uses of known substances.

Section 3(i): Exclusions concerning specified medical treatment methods.

Section 3(j): Exclusions concerning plants and animals and essentially biological processes.

Section 10: Contents and disclosure requirements of patent specifications.

Section 48: Rights of patentees.

These provisions help distinguish patentable genomic inventions from discoveries that remain part of the natural world.

B. Copyright Act, 1957

Relevant provisions include:

Section 2(d): Definition of author.

Section 2(o): Literary work, including computer programmes and compilations.

Section 2(c): Artistic work.

Section 13: Works in which copyright subsists.

Section 14: Meaning of copyright.

Section 17: First ownership.

Section 51: Copyright infringement.

Section 57: Author's special rights.

Section 2(d)(vi) specifically addresses the authorship of computer-generated literary, dramatic, musical or artistic works, identifying the person who causes the work to be created.

This is relevant to AI-generated genomic artwork, although it does not automatically resolve the authorship of every AI-generated genomic output.

C. Biological Diversity Act, 2002

The National Biodiversity Authority plays an important regulatory role in access and benefit-sharing.

The 2023 amendment, effective from 1 April 2024 for the relevant amended provisions, is important because it changed the regulatory treatment of biological resources, research results and intellectual property applications.

A particularly important distinction is that human genetic material is excluded from the amended definition of biological resources. Other relevant biological materials, including qualifying plant, animal and microbial genetic material, may fall within the Act.

Indian Kanoon+1

D. Digital Personal Data Protection Act, 2023

Genomic information may constitute personal data where it relates to an identifiable individual and is processed in digital form.

The Act is relevant to:

Genomic databases.

Digital DNA testing platforms.

Genetic health applications.

Commercial genomic analytics.

Data-sharing arrangements.

AI-based genetic prediction systems.

Its application must be considered alongside the Act's provisions, applicable commencement notifications and rules.

Unlike the GDPR, the Indian DPDP Act does not establish a separate statutory category called special-category genetic data. Nevertheless, the highly identifying nature of genomic information makes careful security, transparency and lawful processing particularly important.

7. Major intellectual property governance challenges

7.1 Genetic sequence ownership disputes

A major difficulty concerns whether a company can claim ownership over a genetic sequence discovered in nature.

The distinction is between:

Discovering an existing genetic sequence.

Isolating genetic material.

Creating a synthetic sequence.

Modifying a sequence through engineering.

Developing a new technical application.

The Myriad Genetics decision establishes an important comparative principle against patenting naturally occurring DNA merely because it has been isolated.

7.2 Multiple inventors and collaborative research

Genomic inventions frequently involve:

Universities.

Biotechnology companies.

Government laboratories.

Clinical researchers.

Data scientists.

Genetic engineers.

AI developers.

Disputes may arise over who actually contributed to the inventive concept.

A researcher's participation in a project does not automatically make that researcher a patent inventor.

Inventorship must be determined according to the applicable legal requirements and actual contribution to the claimed invention.

7.3 Indigenous knowledge and genetic resources

Traditional communities may possess valuable knowledge concerning biological resources, medicinal plants and their applications.

Commercial exploitation without appropriate legal compliance may raise issues involving:

Biopiracy.

Traditional knowledge misappropriation.

Community benefit-sharing.

Access permissions.

Ethical research.

International biodiversity obligations.

The Indian biodiversity framework and the Traditional Knowledge Digital Library are relevant mechanisms in addressing these problems.

7.4 Commercial exploitation without informed consent

A person may provide biological material for one research purpose, while the institution subsequently uses the material for a commercially valuable invention.

This creates difficult questions concerning the scope of consent.

The legal assessment should consider:

Whether the original consent was informed.

Whether commercial research was disclosed.

Whether subsequent use was covered by the consent or another lawful basis.

Whether confidentiality obligations were respected.

Whether applicable ethical and regulatory requirements were satisfied.

Whether the research participant has contractual or other enforceable rights.

The Moore and Greenberg decisions demonstrate why biological-material contribution and commercial IP entitlement must be analysed separately.

7.5 AI and ownership conflicts

AI-assisted genomics introduces additional difficulties:

Who owns an AI-generated DNA design?

Can a company claim exclusive rights over machine-generated genetic inventions?

How should human inventive contributions be identified?

Who is responsible for infringing third-party patents?

Can an AI-generated genomic image qualify for copyright?

Who bears responsibility when an AI system produces a harmful genetic design?

These questions require coordinated patent, copyright, contract, privacy and liability rules.

8. International legal framework

Creative-genomics IP governance is influenced by several international instruments.

A. TRIPS Agreement

TRIPS establishes international intellectual property standards.

Article 27 is particularly relevant because it addresses patentable subject matter and permitted exclusions.

Article 27(3)(b) allows specified exclusions relating to plants and animals, while requiring protection of plant varieties through patents, an effective sui generis system or a combination of both.

B. Convention on Biological Diversity

The Convention promotes fair and equitable sharing of benefits arising from the utilisation of genetic resources.

Its importance lies in preventing the assumption that scientific discovery automatically gives unrestricted commercial entitlement over the biological resources used.

C. Nagoya Protocol

The Nagoya Protocol strengthens the framework for access and benefit-sharing through prior informed consent, where applicable, and mutually agreed terms.

It is particularly relevant to international research collaborations involving genetic resources.

D. UNESCO Universal Declaration on the Human Genome and Human Rights

This declaration provides an ethical and human-rights framework for genomic research.

It emphasises human dignity, fundamental rights and the need to prevent discrimination based on genetic characteristics.

Its provisions are not equivalent to a directly enforceable Indian patent statute, but they are important in developing responsible genomic governance.

9. Regulatory and institutional governance mechanisms

Effective creative-genomics IP governance requires cooperation among different institutions.

Essential governance mechanisms

1. Informed-consent governance

Research institutions should establish transparent procedures explaining the intended collection, storage, research use and relevant commercial exploitation of biological material.

2. Inventorship verification

Patent applications should accurately identify human inventors and their contributions, particularly in collaborative and AI-assisted research.

3. IP ownership agreements

Universities, research institutions and biotechnology companies should establish clear agreements regarding:

Patent ownership.

Copyright ownership.

Licensing.

Revenue sharing.

Confidentiality.

Publication rights.

Researcher recognition.

4. Genetic-data protection

Genomic datasets should be protected against unauthorised access, disclosure, re-identification and misuse.

5. Benefit-sharing

Where applicable, commercial exploitation of biological resources should comply with the Biological Diversity Act and relevant international obligations.

6. Public-interest safeguards

Patent rights should not be treated as absolute rights to restrict scientific research, public health or legitimate access to essential technologies.

7. AI accountability

Organisations should maintain records of human contributions, AI-assisted design processes, source datasets and relevant third-party intellectual property.

10. Emerging legal issues

Creative-genomics intellectual property governance is developing in several new directions.

11. Critical legal analysis

The fundamental difficulty in creative-genomics intellectual property governance is the conflict between private innovation rights and the collective importance of genetic information.

Three competing interests must be balanced.

First: Private innovation rights

Researchers and biotechnology companies need appropriate intellectual property protection to encourage investment, innovation and commercial development.

Second: Individual human rights

Individuals must retain meaningful protections concerning their genetic information, bodily autonomy, privacy and dignity.

Third: Public and scientific interests

Genomic knowledge contributes to public health, disease prevention, scientific progress and medical innovation. Excessively broad intellectual property monopolies may restrict these benefits.

The Myriad Genetics judgment illustrates the distinction between discovering naturally occurring genetic information and creating something technically new.

The Moore judgment illustrates the separation between biological-material interests and ownership of subsequent inventions.

The Monsanto Technology v. Nuziveedu Seeds judgment demonstrates the complexity of enforcing biotechnology patents alongside plant-variety legislation.

Together, these decisions support a governance model in which patent entitlement, biological-material consent, personal information rights and public-interest obligations are assessed independently.

A particularly important distinction is that ownership of an invention does not automatically establish ownership of the human genetic information, biological sample or research contribution from which the invention originated.

12. Suggested reforms for India

The following reforms would strengthen India's creative-genomics IP governance framework.

1. Specialised genomic IP guidelines: Develop guidance distinguishing natural genetic discoveries, engineered genetic constructs, AI-generated inventions and original genomic expression.

2. Human genomic contribution protection: Establish clearer rules concerning commercial use of biological samples and the rights of research participants.

3. AI inventorship standards: Clarify how human inventive contributions should be documented in AI-assisted genomic patent applications.

4. Genomic licensing transparency: Encourage transparent licensing agreements for genetic technologies used in healthcare and public research.

5. Research benefit-sharing: Improve fair benefit-sharing arrangements where legally applicable to biological resources and associated traditional knowledge.

6. Database governance: Establish clear contractual and privacy safeguards for genomic databases and cross-border data transfers.

7. Academic research protection: Develop balanced rules allowing legitimate scientific investigation without unnecessary intellectual property restrictions.

8. Specialised adjudication: Strengthen scientific expertise within intellectual property and biotechnology dispute-resolution mechanisms.

9. Public-interest licensing: Encourage appropriate mechanisms for addressing restrictive licensing practices involving essential genomic technologies.

10. International cooperation: Harmonise relevant standards with WIPO, TRIPS, the Convention on Biological Diversity and the Nagoya Protocol.

13. Important cases: consolidated revision table

Note: These decisions do not all concern creative genomics directly. Some are foundational comparative authorities whose legal principles can be applied to genomic IP disputes. In particular, the US decisions are persuasive comparative materials, not binding Indian precedents.

14. Conclusion

Creative-Genomics Intellectual Property Governance represents an emerging area of biotechnology law combining patent law, copyright, genetic privacy, biological-resource regulation, AI governance, scientific ethics and constitutional rights.

Its central objective is to create a balanced legal framework in which genuine scientific inventions receive protection without allowing unrestricted private monopolisation of naturally occurring genetic information or unjustified exploitation of human biological contributions.

Indian law already provides several important components through the Patents Act, Copyright Act, Biological Diversity Act, constitutional privacy jurisprudence and data-protection legislation. However, the increasing use of artificial intelligence, synthetic genomes, genomic databases and commercial genetic technologies creates a need for more specialised legal standards.

The central governing principle should be that intellectual property protection must reward genuine human and technological innovation while respecting human dignity, genetic privacy, scientific freedom, public health and equitable benefit-sharing.

15. Important legal propositions for academic research

The following propositions can be used as the foundation for a research paper or dissertation:

Natural genetic discoveries should be distinguished from patentable technological inventions.

Biological-material contribution does not automatically confer patent ownership.

Patent ownership does not eliminate independent privacy and consent obligations.

Copyright protects original genomic expression rather than genetic facts themselves.

AI-assisted genomic inventions require accurate identification of legally recognised inventors.

Commercial use of biological resources must comply with applicable access and benefit-sharing legislation.

Genomic database ownership does not confer unlimited control over personal genetic information.

Intellectual property rights must be balanced against constitutional rights and public-health interests.

International genomic collaborations require transparent ownership and licensing arrangements.

Creative-genomics governance should recognise both scientific innovation and the legitimate interests of individuals and communities.

Overall academic significance: This subject is particularly suitable for advanced research in biotechnology law, intellectual property law, constitutional law, artificial intelligence regulation and genetic-data governance.

Further research direction: The next useful topic is AI-Generated Genomic Inventions: Patentability, Inventorship, Ownership and Accountability Doctrine, which develops the most challenging emerging aspect of creative-genomics IP governance.